Vindesine information

Vindesine
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy; category	AU: D; ;
Routes of; administration	Intravenous
ATC code	L01CA03 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	65-75%
Metabolism	Hepatic (CYP3A4-mediated)
Elimination half-life	24 hours
Excretion	Biliary and renal
Identifiers
	IUPAC name methyl (5S,7S,9S)- 9-[(2β,3β,4β,5α,12β,19α)- 3-(aminocarbonyl)- 3,4-dihydroxy- 16-methoxy- 1-methyl- 6,7-didehydroaspidospermidin- 15-yl]- 5-ethyl- 5-hydroxy- 1,4,5,6,7,8,9,10-octahydro- 2H- 3,7-methanoazacycloundecino[5,4-b]indole- 9-carboxylate;
CAS Number	53643-48-4 ; Sulfate: 59917-39-4 ;
PubChem CID	40839;
DrugBank	DB00309 ;
ChemSpider	37302 ;
UNII	RSA8KO39WH; Sulfate: CPH2U7DNDY ;
KEGG	D01769 ;
ChEBI	CHEBI:36373 ;
ChEMBL	ChEMBL219146 ;
CompTox Dashboard (EPA)	DTXSID6023739 ;
ECHA InfoCard	100.053.330
Chemical and physical data
Formula	C43H55N5O7
Molar mass	753.941 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OC)[C@]4(c2c(c1ccccc1[nH]2)CCN3C[C@](O)(CC)C[C@@H](C3)C4)c5c(OC)cc6c(c5)[C@@]89[C@@H](N6C)[C@@](O)(C(=O)N)[C@H](O)[C@@]7(/C=C\CN([C@@H]78)CC9)CC;
	InChI InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1 ; Key:HHJUWIANJFBDHT-KOTLKJBCSA-N ;
	(verify)

Vindesine, also termed Eldisine, is a semisynthetic vinca alkaloid derived from the flowering plant Catharanthus roseus.^[1] Like the natural (e.g. vinblastine and vincristine) and semisynthetic vinca alkaloids (e.g. vinorelbine and vinflunine) derived from this plant, vindesine is an inhibitor of mitosis that is used as a chemotherapy drug.^[2] By inhibiting mitosis, vinedsine blocks the proliferation of cells, particularly the rapidly proliferation cells of certain types of cancer. It is used, generally in combination with other chemotherapeutic drugs, in the treatment of various malignancies such as leukaemia, lymphoma, melanoma, breast cancer, and lung cancer.^[3]

^ Mondal A, Gandhi A, Fimognari C, Atanasov AG, Bishayee A (September 2019). "Alkaloids for cancer prevention and therapy: Current progress and future perspectives". European Journal of Pharmacology. 858: 172472. doi:10.1016/j.ejphar.2019.172472. PMID 31228447. S2CID 195298770.
^ Martino E, Casamassima G, Castiglione S, Cellupica E, Pantalone S, Papagni F, Rui M, Siciliano AM, Collina S (September 2018). "Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead". Bioorganic & Medicinal Chemistry Letters. 28 (17): 2816–2826. doi:10.1016/j.bmcl.2018.06.044. PMID 30122223. S2CID 52039135.
^ "Vindesine (Eldisine) | Cancer information | Cancer Research UK".

[pmid31228447-1] Mondal A, Gandhi A, Fimognari C, Atanasov AG, Bishayee A (September 2019). "Alkaloids for cancer prevention and therapy: Current progress and future perspectives". European Journal of Pharmacology. 858: 172472. doi:10.1016/j.ejphar.2019.172472. PMID 31228447. S2CID 195298770.

[pmid30122223-2] Martino E, Casamassima G, Castiglione S, Cellupica E, Pantalone S, Papagni F, Rui M, Siciliano AM, Collina S (September 2018). "Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead". Bioorganic & Medicinal Chemistry Letters. 28 (17): 2816–2826. doi:10.1016/j.bmcl.2018.06.044. PMID 30122223. S2CID 52039135.

[3] "Vindesine (Eldisine) | Cancer information | Cancer Research UK".

Vindesine information

and 27 Related for: Vindesine information

Vindesine

DAVA

Vinca major

MVP

Schedule H

Tretinoin

Methotrexate

Chemotherapy

Lifileucel

Celecoxib

Hydroxycarbamide

Vinca alkaloid

Mitomycin C

FOLFIRI

Abemaciclib

Paclitaxel

Nelarabine

Nocodazole

Antimetabolite

Doxorubicin

Nitrogen mustard

Carboplatin

Talazoparib

Cytarabine

Fluorouracil

ATC code L01

Temozolomide

Clinical data


AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	AU: D
Routes of administration	Intravenous
ATC code	L01CA03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	65-75%
Metabolism	Hepatic (CYP3A4-mediated)
Elimination half-life	24 hours
Excretion	Biliary and renal
Identifiers
IUPAC name methyl (5S,7S,9S)- 9-[(2β,3β,4β,5α,12β,19α)- 3-(aminocarbonyl)- 3,4-dihydroxy- 16-methoxy- 1-methyl- 6,7-didehydroaspidospermidin- 15-yl]- 5-ethyl- 5-hydroxy- 1,4,5,6,7,8,9,10-octahydro- 2H- 3,7-methanoazacycloundecino[5,4-b]indole- 9-carboxylate
CAS Number	53643-48-4^Y Sulfate: 59917-39-4^Y
PubChem CID	40839
DrugBank	DB00309^Y
ChemSpider	37302^Y
UNII	RSA8KO39WH Sulfate: CPH2U7DNDY^Y
KEGG	D01769^Y
ChEBI	CHEBI:36373^Y
ChEMBL	ChEMBL219146^Y
CompTox Dashboard (EPA)	DTXSID6023739
ECHA InfoCard	100.053.330
Chemical and physical data
Formula	C₄₃H₅₅N₅O₇
Molar mass	753.941 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C(OC)[C@]4(c2c(c1ccccc1[nH]2)CCN3C[C@](O)(CC)C[C@@H](C3)C4)c5c(OC)cc6c(c5)[C@@]89[C@@H](N6C)[C@@](O)(C(=O)N)[C@H](O)[C@@]7(/C=C\CN([C@@H]78)CC9)CC
InChI InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1^Y Key:HHJUWIANJFBDHT-KOTLKJBCSA-N^Y
(verify)